SEQUANA MEDICAL N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 EUR | +1.27% |
|
+1.59% | -60.00% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Sequana Full Year Re...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
Calendar
2024-09-04
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.6
EUR
Average target price
5.967
EUR
Spread / Average Target
+272.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.00% | 52.48M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- SEQUA Stock
- News Sequana Medical N.V.
- Transcript : Sequana Medical NV, 2021 Earnings Call, Apr 12, 2022
